Form 8-K

8-K — Nuwellis, Inc.

Accession: 0001140361-26-034367

Filed: 2026-08-26

Period: 2026-08-25

CIK: 0001506492

SIC: 3845 (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ef20081099_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (ef20081099_ex99-1.htm)

GRAPHIC (ef20081099_ex99-1slide1.jpg)

GRAPHIC (ef20081099_ex99-1slide2.jpg)

GRAPHIC (ef20081099_ex99-1slide3.jpg)

GRAPHIC (ef20081099_ex99-1slide4.jpg)

GRAPHIC (ef20081099_ex99-1slide5.jpg)

GRAPHIC (ef20081099_ex99-1slide6.jpg)

GRAPHIC (ef20081099_ex99-1slide7.jpg)

GRAPHIC (ef20081099_ex99-1slide8.jpg)

GRAPHIC (ef20081099_ex99-1slide9.jpg)

GRAPHIC (ef20081099_ex99-1slide10.jpg)

GRAPHIC (ef20081099_ex99-1slide11.jpg)

GRAPHIC (ef20081099_ex99-1slide12.jpg)

GRAPHIC (ef20081099_ex99-1slide13.jpg)

GRAPHIC (ef20081099_ex99-1slide14.jpg)

GRAPHIC (ef20081099_ex99-1slide15.jpg)

GRAPHIC (ef20081099_ex99-1slide16.jpg)

GRAPHIC (ef20081099_ex99-1slide17.jpg)

GRAPHIC (ef20081099_ex99-1slide18.jpg)

GRAPHIC (ef20081099_ex99-1slide19.jpg)

GRAPHIC (ef20081099_ex99-1slide20.jpg)

GRAPHIC (ef20081099_ex99-1slide21.jpg)

GRAPHIC (ef20081099_ex99-1slide22.jpg)

GRAPHIC (ef20081099_ex99-1slide23.jpg)

GRAPHIC (ef20081099_ex99-1slide24.jpg)

GRAPHIC (ef20081099_ex99-1slide25.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: ef20081099_8k.htm · Sequence: 1

false000150649200015064922026-08-252026-08-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 25, 2026

Nuwellis, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware

001-35312

No. 68-0533453

(State or Other Jurisdiction of Incorporation or Organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

12988 Valley View Road,

Eden Prairie, MN 55344

(Address of Principal Executive Offices) (Zip Code)

(952) 345-4200

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

NUWE

NASDAQ

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the

following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this

chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new

or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD Disclosure.

On August 25, 2026, Nuwellis, Inc. (the

“Company”) posted an updated corporate presentation to its website at ir.nuwellis.com, which the Company may use from time to time in presentations, investor communications or conferences. A copy of the corporate presentation is attached

as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”) and is incorporated herein by reference.

Information contained on or accessible through any website reference in the corporate presentation is not part of, or incorporated by reference in,

this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the corporate presentation is as inactive textual references only.

The information in this Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of

Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that

Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company’s submission of this

Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Forward-Looking Statements

Exhibit 99.1 hereto contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based

on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange

Commission, including that actual events or results may differ materially from those in the forward-looking statements.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Number

Description

99.1

Corporate Presentation, dated August 25, 2026

104

Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the

undersigned hereunto duly authorized.

Date: August 25, 2026

NUWELLIS, INC.

By:

/S/ Michael K. McCormick

Name:

Michael K. McCormick

Title:

President and Chief Executive Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: ef20081099_ex99-1.htm · Sequence: 2

Exhibit 99.1

August 2026 INVESTOR PRESENTATION NASDQ: NUWE

Forward-Looking Statements This presentation contains forward‐looking statements

within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act, as amended regarding our plans, expectations, beliefs, estimates, goals and outlook for the future that are intended

to be covered by the Private Securities Litigation Reform Act of 1995. Except for statements of historical fact, all forward‐looking statements are management’s present expectations and are not guarantees of future events and are subject to a

number of known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from those expressed in, or implied by, such forward-looking statements. In some cases, you can identify forward-looking

statements by terminology such as “may,” “will,” “could,” “would,” “should,” “plan,” “predict,” “potential,” “project,” “promising,” “expect,” “estimate,” “anticipate,” “intend,” “goal,” “strategy,” “milestone,” and similar expressions and

variations thereof. Various factors could cause actual results to differ materially from these statements including our ability to execute on our commercial strategy and to grow our Aquadex® business, the possibility that we may be unable to

raise sufficient funds necessary for our anticipated operations, our clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to

increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our expectations regarding anticipated synergies with and benefits of the Aquadex business, our business

strategy, market size, potential growth opportunities and the other risks set forth under the caption “Risk Factors” and elsewhere in our periodic and other reports filed with the U.S. Securities and Exchange Commission (“SEC”), including our

Annual Report on Form 10‐K for the fiscal year ended December 31, 2025 and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this presentation, and we undertake no obligation to update any

forward-looking statements contained in this presentation as a result of new information, future events or otherwise. Although the Company believes that the forward‐looking statements are reasonable and based on information currently available,

it can give no assurances that the Company’s expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. 2

Investment Highlights 3 Best-in-class ultrafiltration technology Aquadex® is a

clinically proven system for precise, predictable fluid removal reducing readmissions and improving outcomes Streamlined solution that is cost-effective, workflow-friendly, and backed by comprehensive clinical support Expanding our platform

into new indications and leveraging our commercial infrastructure through partnerships Planned label expansion and new products in development broaden our offering Partnerships that leverage sales team and expand our cardiorenal

solutions Addressing a large and growing market opportunity Total platform potential opportunity exceeds $4.2 billion in the U.S. Accelerating growth in pediatric care Adopted by leading children’s hospitals Pediatrics patients

represents 50% of revenues Improving financial metrics with revenue growth and expanding margins 1H26 revenue growth of 20% over prior-year period 2Q26 gross margins improved to 76% compared to 56% in prior-year period Cash runway through

2Q27 to implement near-term growth initiatives See Appendix for Market Opportunity sources.

Fluid Overload Drives Mortality and Hospitalizations 4 Higher ICU

Mortality Fluid overload is associated with significantly increased 90-day mortality in critically ill ICU patients2 Increased Pediatric Mortality Fluid overload is linked to substantially higher mortality in critically ill children3-4 Key

driver of hospitalizations ~90% of HF hospitalizations are associated with symptoms of fluid overload5 Critical Care Pediatric Heart Failure Fluid Overload is a leading cause of costly hospital readmission post 30 days following cardiac

surgery1 1. Iribarne A, et al. Ann Thorac Surg. 2014; 98(4): 1274-80. 2. Vaara ST et al. Crit Care.2012; 16: 1-11. 3 Sutherland SM, et al. Am J Kidney Disease. 2010; 5(2): 316-25. 4 Gillespie RS, et al. Ped Nephro. 2004; 19(12): 1394-99. 5

Costanzo MR, et al. JACC. 2017 May 16;69(19):2428-2445.

A $4.2B U.S. Clinical Addressable Market Opportunity 5 Nuwellis current

platform and future products collectively address an enormous market opportunity across five segments Critical Care Inpatient HF Outpatient HF Pediatrics Fluid Monitoring Sources: See

Appendix $900MMarket $1BMarket $770MMarket $160MMarket $1.4BMarket

6 Our Solution Aquadex®A clinically proven therapy for precise, predictable

fluid removal1 Low-volume ultrafiltration designed for critically ill patients Allows controlled fluid removal when diuretics fail Adopted in ICU, cardiac surgery, and pediatric critical care programs 1Pinney, S et. al., J AM Coll Cardiol

HF, 2025, ISSN 2213-1779 https://doi.org/10.1016/j.jchf.2024.11.018

Aquadex System: Predictable and Precise Fluid Removal Filtered blood returns to

the patient via the infusion line 5 Blood is taken from the patient via the withdrawal line using proprietary catheter technology 1 The blood is pushed through the filter by the blood pump (0-40 ml per minute) 2 The ultrafiltration pump

withdraws fluid across the filter membrane using negative pressure Hematocrit sensor monitors preset hematocrit limits 3 Ultrafiltration pump can pull 0-500 ml of fluid per hour 4 7

Aquadex System: High-Margin Recurring Revenue Model 8 Flexible acquisition

models: purchase, lease or rental Increasing utilization as adoption spreads One-time CapEx purchase Price point: high-value Single-use for every treatment High-margin Aquadex Console Capital Equipment Disposables Recurring Revenue

Why Hospitals Are Adopting Precision Fluid Management 9 Mortality Acute Kidney

Injury Risk (AKI) Readmissions Pediatrics Fluid overload > 5% body-weight gain is associated with significantly higher mortality across ICU cohorts.1 Postoperative AKI drives higher mortality and longer ICU/PICU stays.2 In HF & CV

surgery, persistent fluid overload at discharge predicts unplanned readmission within 30 days of discharge.3 Aquadex’s low priming blood volume (35 ml) can mitigate complications of other therapies used in children with AKI or ESKD.4

1Messmer AS, Zingg C, Müller M, Gerber JL, Schefold JC, Pfortmueller CA. Fluid overload and mortality in adult critical care patients: A systematic review and meta-analysis of observational studies. Crit Care Med. 2020;48(12):1862–1870

2McIlroy DR, Engelman DT, Shaw AD, et al. Perioperative Quality Initiative (POQI) and Enhanced Recovery After Surgery (ERAS) Cardiac Society Joint Consensus Statement on Adult Cardiac Surgery–Associated Acute Kidney Injury (CSA-AKI) 3Abraham

WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomized controlled trial. Lancet. 2011;377(9766):658–666 4Menon S, Broderick J, Munshi R, et al. Kidney Support in Children using

an Ultrafiltration Device: A Multicenter, Retrospective Study. Clin J Am Soc Nephrol. 2019;14(10):1432-1440. doi:10.2215/CJN.03240319

Commercial Execution Demonstrating Broad-Based Growth 10 Broad Clinical

Coverage Pediatric - 29% growth* Pediatric Nephrology & Critical Care Critical Care – 28% growth* ICU/Intensivists & Cardiac Surgery Heart Failure – 27% growth* Heart failure Cardiology *H1 revenue growth YOY Complex Therapy Sales

Capability Experienced sales and clinical teams Expertise navigating multi-department adoption Ability to establish new therapy programs Performance 20% H1 revenue growth vs prior year 72% gross margin up from 56% prior year ~135 active

hospital accounts, including leading U.S. academic hospitals and Centers of Excellence

11 Providers are increasingly seeking out Aquadex for use with children,

validating both the clinical demand and the growing commercial footprint in pediatric centers Expansion of Aquadex labelled weight indication to > 5kg to facilitate broader adoption Development of Vivian as the next-generation pediatric

renal support platform supporting patients as small as 2.5kg Pediatric Adoption Validates Both the Market Need and the Pathway for a Dedicated Solution Installations in 47 Leading U.S. Children’s Hospitals Integrated Into NICUs, PICUs, and

CVICUs Sustained Utilization Growth Establishing a significant pediatric footprint with substantial opportunity for expansion Providing precise, gentle fluid removal for critically ill children who require controlled

ultrafiltration Signaling increasing clinical reliance and expanding need across pediatric care teams Future Pediatric Product Offering to Address Major Unmet Need

Aquadex Pediatric Growth Expansion 12 Successfully completed FDA pre-submission

meeting for proposed Aquadex label expansion to pediatric patients ≥5 kg Proposed expansion supported by: Established body of published pediatric clinical experience Real-world utilization at leading pediatric centers Growing physician

adoption in patients weighing 5–20 kg Strategic impact: Addresses significant unmet need for controlled fluid management in low-weight pediatric patients Expands long-term pediatric market opportunity Company anticipates FDA submission by

year-end 2026

Critical Care: Addressing Fluid Overload Following Cardiac Surgery 13 The

ProblemCardiac surgery can require significant fluid administration, contributing to post-operative fluid overload1 1 DeVore A, et al. Curr Treat Opts Cardiovasc Med. 2014; 16(2):283. 2 Bundgaard-Nielsen M, et al. Acta Anaesthesiol Scand 2009;

53:843-851. 3 Wiedemann HP, et al. N Engl J Med. 2006, 354:2564-75. 4 Stein A, et al. Critical Care. 2012; 16(R99):1-9. 5 Miller TE, et al. Can J Anesthes. 2015; 62:158-68. Aquadex SolutionSimple, predictable fluid removal when precise volume

management is needed Clinical ValueReduces time to be extubated2,3 Shortens time in post op care and ICU length of stay3,4 Improves outcomes2-5 28%Growth H1 over prior year

Heart Failure: Breaking the Cycle of Fluid Overload and Readmission 14 The

Problem Persistent congestion drives repeat hospitalization Aquadex Solution Precise, predictable fluid removal – for patients with fluid overload when diuretics are inadequate 60% Reduction in HF Events at 30 days – Adjustable

ultrafiltration vs. adjustable IV diuretics6 27% H1 2026 Growth – Heart Failure revenue vs prior year 1Gheorghiade M, et al. Eur Heart J Suppl. 2005; 7:B13-9. 2Premier Applied Sciences Database. 3Costanzo MR, et al. J Am Coll Cardiol. 2017,

May 16; 69(19):2428-2445. 4Emani S, et al. (2012) Poster from The 16th Annual Scientific Meeting of HFSA. 5Chung ES, O’Brien TM, et al. Korean Circ J. 2014; 44(3):151-61. ⁶ Pinney SP, DeVita MV, Redfors B, et al. Ultrafiltration for

Management of Decompensated Heart Failure: A Reappraisal of AVOID-HF. JACC Heart Fail. 2025;13(4):657-659.

Expanding Beyond Fluid Removal into Critical Care Solutions 15 Current

Commercial Engine Near-term Expansion Long-term Pediatric Upside Leveraging our ICU & pediatric commercial infrastructure to expand into adjacent monitoring and therapy markets ClarityPRIME Precision fluid removal platform deployed

across ICU and pediatric centers Co-Promotion and Distribution for AtriAmp® Cardiac Rhythm Monitoring Enhancing capabilities with SmartView, High Flow and multiple filters Automated urine output and electrolyte monitoring for critical

care Next-generation pediatric renal support platform *ClarityPRIME is currently under development and is not FDA cleared.

R&D Expanding Aquadex Capabilities to Extend Platform Use 16 SmartView

Provides Real-time Insights Expanding Filtration Range Built For High Flow Multiple Filters For Critical Care Optimizes therapy and supports decisions Seamlessly integrated with EMR and hospital systems Simplifies workflows and improves

productivity Operating range expanded from to 100 mL/min (from 40 mL/min ) Improves filtration efficiency and extends filter life Reduces consumable use and procedural costs Performs in high pressure critical care settings, including

ECMO Adapted to run adsorption and other modality filters Applications include drug overdose/poisoning, chemotherapy filtration, autoimmune disease, sepsis Unlocks new solutions for critical care More Capability. More Filters. More

Patients. Same Trusted Aquadex Platform.

17 Introducing Vivian™Developing our dedicated pediatric solution Currently in

development and supported by a $3M NIH grant. Ultra-low ECV (29–67 mL) for neonatal + small-child CRRT Engineered for patients as small as 2.5kg with unique Hematocrit and SVO2 sensor safety features Integrated UF, CVVH, and CVVHD therapies

in one platform *Vivian is currently under development and is not FDA cleared.

ClarityPRIME* Systems Expands Nuwellis into Smart Fluid Monitoring 18 Addresses

A Critical Need in Cardiac Surgery & Critical Care Enters a High-growth, Underpenetrated Market Fits Directly Into Our Existing Sales Channel Real-time urine output and electrolyte data are essential for early detection of AKI. Targets

the emerging automated urine monitoring segment within the broader urinalysis and critical care monitoring market. RMS price point ($2,500 console; $60–80 kits) aligns with Aquadex’s critical care sales and our common call point. Commercial

Launch Expected in 2H 2027 1 2 3 *ClarityPRIME is currently under development and is not FDA cleared.

Co-Promotion and Distribution Agreements withfor AtriAmp® Cardiac Rhythm

Monitoring 19 Ability to expand revenue per customer by leveraging critical-care commercial infrastructure FDA cleared, sterile, single-patient-use device for adult and pediatric patients with temporary epicardial pacing wires Improved

atrial signal visibility supports faster, more accurate identification of post-operative arrhythmias Enables more informed clinical decision-making AtriAmp® Agreement Value Drivers Leverages existing sales infrastructure Deepens customer

relationships with complementary product supported by same commercial and clinical team Recurring disposable revenue with limited incremental investment Exclusive Distribution Opportunity U.S. rights (ex-NY) · Recurring product

revenue Performance Criteria Pre-established milestones evaluated 6-Month Co-Promotion Pilot ~11 Western states · Current sales team

Strategy Drives Growth with Operating Discipline Drive physician adoption within

new and existing hospitals Expand label to pediatric patients > 5kg Enhance system with workflow improvements and data integration Recent acquisition extends cardiorenal platform Clarity PRIME targeted launch in 2027 Ability to leverage

existing sales channel Recent announcement with Atrility Medical Strategic fit with pediatric and critical care franchise Continue to drive revenue growth (1H26 revenue growth of 20%) Expand grow margins (2Q26 gross margins of 76% vs. 56%

in 2Q25) Expect further operating leverage as recurring utilization continues to scale Develop Vivian CRRT system for pediatric patients > 2.5kg IDE submission with the the FDA expected in 2Q 2028 20 Increase Aquadex Market

Penetration Develop and Market New Products in Cardiorenal Care Pursue Select Distribution Partnerships to Leverage Commercial Infrastructure Improve Operating Leverage Execute Long-Term Portfolio Vision

Target Milestones 21 Target Date Milestone Q3 2026 Publication of ULTRA-Peds

data Q4 2026 FDA 510k submission for Pediatric indication expansion to 5kg (from 20kg) Q4 2026 Additional strategic partnership/distribution agreements H1 2027 Launch of SmartView for Aquadex H2 2027 Launch of expanded high flow range

for Aquadex H2 2027 Clarity PRIME commercial launch Q4 2027 / Q1 2028 Launch of multiple filters for Aquadex

Nuwellis Leadership Team 22 Over 200 years of combined experience in clinical

practice and the medical device industry, including major tenures at J&J, Boston Scientific, Medtronic, and Abbott/St. Jude Medical Ryan Marthaler Vice President of Product Marketing and Business Development Betsy

Riemenschneider Regional Vice President of Sales Carisa Schultz Chief Financial Officer Kelsey Newell Senior Director of Medical Affairs Neil Ayotte Sr. Vice President, General Counsel & Compliance Officer Kim Anderson Vice

President of Operations Scott Campbell Regional Vice President of Sales David Lerner Vice President of Research and Development Mike McCormick President and CEO

Financial Highlights 23 Capitalization as of August 10, 2026 Common

Equivalents Common Stock 3,647,264 Preferred Stock* 5,859 Warrants (weighted avg. exercise price: $10.66) 2,102,300 Options (weighted avg. exercise price: $72.89) 1,722 Fully Diluted 5,757,145 H1 2026 Revenue Growth +20% YoY Q2

2026 Gross Margin 76% versus 55% in year-ago period * See SEC filings for Preferred Stock terms and anti-dilution provisions.

Contact Details Investor & Media Relations: CORE IRYvonne

Briggs ir@nuwellis.com Media Inquiries: CORE PRKati Waldenburg media@nuwellis.com

Appendix Market Size Sources Heart Failure – Inpatient Incidence of HF:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494150/ Annual HF Hospitalizations: Costanzo MR, et al. J Am Coll Cardiol. 2017 May 16;69(19):2428-2445 Insufficient diuretic response:

https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.115.002370?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed Heart Failure – Outpatient Incidence of HF:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494150/ Annual HF Hospitalizations: Costanzo MR, et al. J Am Coll Cardiol. 2017 May 16;69(19):2428-2445 Diuretic resistance rate:

https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.115.002370?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed Critical Care VADs:

https://www.grandviewresearch.com/industry-analysis/ventricular-assist-devices-market CABG: https://www.grandviewresearch.com/industry-analysis/coronary-artery-bypass-graft-cabg-market Valves:

https://idataresearch.com/over-182000-heart-valve-replacements-per-year-in-the-united-states/ Liver Transplants: https://www.healthline.com/health/liver-transplant-survival Liver Disease: https://www.ncbi.nlm.nih.gov/pubmed/25291348 Kidney

Disease: https://www.kidney.org/news/newsroom/factsheets/KidneyDiseaseBasics Sepsis: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557150/ ECMO: https://www.uclahealth.org/medical-services/heart/ecmo/research/statistics Pediatrics Renal

Replacement/AKI: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789331/#:~:text=The%20hospitalized%20population%20at%20risk,are%20shown%20in%20Table%201 Heart Disease:

https://www.cdc.gov/ncbddd/heartdefects/data.html#:~:text=Congenital%20heart%20defects%20are%20conditions,the%20United%20States%20each%20year Pediatric Transplantations: https://www.organdonor.gov/about/donors/child-infant.html Pediatric

ECMO: https://www.ncbi.nlm.nih.gov/pubmed/23246046 25

GRAPHIC

Filename: ef20081099_ex99-1slide1.jpg · Sequence: 6

Binary file (114082 bytes)

Download ef20081099_ex99-1slide1.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide2.jpg · Sequence: 7

Binary file (261539 bytes)

Download ef20081099_ex99-1slide2.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide3.jpg · Sequence: 8

Binary file (169117 bytes)

Download ef20081099_ex99-1slide3.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide4.jpg · Sequence: 9

Binary file (158107 bytes)

Download ef20081099_ex99-1slide4.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide5.jpg · Sequence: 10

Binary file (161258 bytes)

Download ef20081099_ex99-1slide5.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide6.jpg · Sequence: 11

Binary file (105684 bytes)

Download ef20081099_ex99-1slide6.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide7.jpg · Sequence: 12

Binary file (136909 bytes)

Download ef20081099_ex99-1slide7.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide8.jpg · Sequence: 13

Binary file (123368 bytes)

Download ef20081099_ex99-1slide8.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide9.jpg · Sequence: 14

Binary file (218131 bytes)

Download ef20081099_ex99-1slide9.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide10.jpg · Sequence: 15

Binary file (115400 bytes)

Download ef20081099_ex99-1slide10.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide11.jpg · Sequence: 16

Binary file (166075 bytes)

Download ef20081099_ex99-1slide11.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide12.jpg · Sequence: 17

Binary file (162359 bytes)

Download ef20081099_ex99-1slide12.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide13.jpg · Sequence: 18

Binary file (114490 bytes)

Download ef20081099_ex99-1slide13.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide14.jpg · Sequence: 19

Binary file (120946 bytes)

Download ef20081099_ex99-1slide14.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide15.jpg · Sequence: 20

Binary file (129864 bytes)

Download ef20081099_ex99-1slide15.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide16.jpg · Sequence: 21

Binary file (168527 bytes)

Download ef20081099_ex99-1slide16.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide17.jpg · Sequence: 22

Binary file (104733 bytes)

Download ef20081099_ex99-1slide17.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide18.jpg · Sequence: 23

Binary file (124894 bytes)

Download ef20081099_ex99-1slide18.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide19.jpg · Sequence: 24

Binary file (158358 bytes)

Download ef20081099_ex99-1slide19.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide20.jpg · Sequence: 25

Binary file (144640 bytes)

Download ef20081099_ex99-1slide20.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide21.jpg · Sequence: 26

Binary file (86546 bytes)

Download ef20081099_ex99-1slide21.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide22.jpg · Sequence: 27

Binary file (119478 bytes)

Download ef20081099_ex99-1slide22.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide23.jpg · Sequence: 28

Binary file (95143 bytes)

Download ef20081099_ex99-1slide23.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide24.jpg · Sequence: 29

Binary file (118629 bytes)

Download ef20081099_ex99-1slide24.jpg

GRAPHIC

Filename: ef20081099_ex99-1slide25.jpg · Sequence: 30

Binary file (195037 bytes)

Download ef20081099_ex99-1slide25.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 32

v3.26.1

Document and Entity Information

Aug. 25, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 25, 2026

Entity File Number

001-35312

Entity Registrant Name

Nuwellis, Inc.

Entity Central Index Key

0001506492

Entity Incorporation, State or Country Code

Entity Tax Identification Number

68-0533453

Entity Address, Address Line One

12988 Valley View Road

Entity Address, City or Town

Eden Prairie

Entity Address, State or Province

Entity Address, Postal Zip Code

55344

City Area Code

952

Local Phone Number

345-4200

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

NUWE

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration